Literature DB >> 29395208

Impact of induction chemoradiotherapy on pulmonary function after lobectomy for lung cancer.

Hiroaki Nomori1, Atsushi Shiraishi2, Yue Cong3, Kazufusa Shoji4, Masafumi Misawa5, Hiroshi Sugimura3, Yu Oyama6.   

Abstract

OBJECTIVE: Our study aim was to determine whether there are differential changes in whole-lung and regional lung functions after lobectomy for lung cancer between propensity score-matched patients treated with and without induction chemoradiotherapy, by using single-photon emission computed tomography lung perfusion.
METHODS: This study was a retrospective matched cohort study of consecutively acquired data. Pulmonary function test and perfusion scintigraphy were conducted before lobectomy and 6 months after lobectomy in patients treated with induction therapy (n = 72) and in those not treated (n = 170), for measuring functional changes of whole lung, contralateral lung, and lobes. After exact matching on resected lobe site, propensity scores for age, smoking status, preoperative pulmonary functions, and predicted postoperative pulmonary function were used to match the groups.
RESULTS: After the matching, 46 patients were selected from the groups. Standardized mean differences of the 5 matched variables were <0.1. Whole lung function significantly decreased after lobectomy in the induction therapy group than in the noninduction therapy group (P < .001). Although ipsilateral preserved lobe function before surgery was not different between the groups (P = .33), postoperative value was significantly lower in the induction therapy group than in the noninduction therapy group (P < .001). Although both groups showed a significant increase of contralateral lung function after lobectomy (P < .01), the increases were not significantly different between the groups (P = .81).
CONCLUSIONS: Induction chemoradiotherapy was associated with reduced pulmonary function after lobectomy because of a decrease in ipsilateral preserved lobe function, which could be caused by the chronic effects of the induction chemoradiotherapy.
Copyright © 2017 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  induction chemoradiotherapy; lobectomy; lung cancer; perfusion scintigraphy; pulmonary function

Mesh:

Year:  2017        PMID: 29395208     DOI: 10.1016/j.jtcvs.2017.12.081

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Impact of age on the recovery of six-minute walking distance after lung cancer surgery: a retrospective cohort study.

Authors:  Hiroshi Saito; Atsushi Shiraishi; Hiroaki Nomori; Hiroki Matsui; Kazuki Yoshida; Yuya Matsue; Tomoko Fujii; Kennosuke Kawama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-09-04

2.  Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer.

Authors:  James G Connolly; Megan Fiasconaro; Kay See Tan; Michael A Cirelli; Gregory D Jones; Raul Caso; Daniel E Mansour; Joseph Dycoco; Jae Seong No; Daniela Molena; James M Isbell; Bernard J Park; Matthew J Bott; David R Jones; Gaetano Rocco
Journal:  J Thorac Cardiovasc Surg       Date:  2021-12-23       Impact factor: 6.439

3.  Pulmonary function changes after thoracoscopic lobectomy versus intentional thoracoscopic segmentectomy for early-stage non-small cell lung cancer.

Authors:  Liang Chen; Zhitao Gu; Boyu Lin; Weimin Wang; Ning Xu; Yuan Liu; Chunyu Ji; Wentao Fang
Journal:  Transl Lung Cancer Res       Date:  2021-11

4.  Is sleeve lobectomy safe after induction therapy?-a systematic review and meta-analysis.

Authors:  Louis-Emmanuel Chriqui; Céline Forster; Alban Lovis; Hasna Bouchaab; Thorsten Krueger; Jean Yannis Perentes; Michel Gonzalez
Journal:  J Thorac Dis       Date:  2021-10       Impact factor: 3.005

Review 5.  Rapid Recovery of Postoperative Pulmonary Function in Patients With Lung Cancer and Influencing Factors.

Authors:  Yang Fuzhi; Tang Dongfang; Fu Wentao; Wang Jing; Wu Yingting; Mo Nianping; Gao Wen; Shen Xiaoyong
Journal:  Front Oncol       Date:  2022-07-11       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.